Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Special collections
JITC
Commentary/Editorials
Commentary/Editorials
It’s a long way to the top (if you want to personalize immunotherapy)
Sarah
Haebe
,
Oliver
Weigert
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
6;
DOI:
10.1186/s40425-016-0207-0
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Stefan N.
Symeonides
,
Stephen M.
Anderton
,
Alan
Serrels
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
17;
DOI:
10.1186/s40425-017-0217-6
Tissue-resident lymphocytes: sentinel of the transformed tissue
Saïda
Dadi
,
Ming O.
Li
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
41;
DOI:
10.1186/s40425-017-0244-3
Potassium channels of T lymphocytes take center stage in the fight against cancer
Laura
Conforti
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
2;
DOI:
10.1186/s40425-016-0202-5
Immunotherapy resistance: the answers lie ahead – not in front – of us
Miles C.
Andrews
,
Jennifer A.
Wargo
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
10;
DOI:
10.1186/s40425-017-0212-y
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis
Marc-Elie
Nader
,
Matthew
Zibelman
,
Jeffrey N.
Myers
,
Paul W.
Gidley
,
Natasha
Pollak
,
Anthony J.
Olszanski
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
24;
DOI:
10.1186/s40425-017-0226-5
The why, what, and how of the new FACT standards for immune effector cells
Marcela V.
Maus
,
Sarah
Nikiforow
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
36;
DOI:
10.1186/s40425-017-0239-0
Letter to the editor
Camilo E
Fadul
,
Jan L
Fisher
,
Thomas H
Hampton
,
Marc S
Ernstoff
Journal for ImmunoTherapy of Cancer
Dec 2014,
2
(1)
22;
DOI:
10.1186/2051-1426-2-22
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
Michael K
Wong
,
Howard L
Kaufman
,
Gregory A
Daniels
,
David F
McDermott
,
Sandra
Aung
,
James N
Lowder
,
Michael A
Morse
Journal for ImmunoTherapy of Cancer
Dec 2014,
2
(1)
20;
DOI:
10.1186/2051-1426-2-20
Complement controls the immune synapse and tumors control complement
Alan
Herbert
Journal for ImmunoTherapy of Cancer
Dec 2020,
8
(2)
e001712;
DOI:
10.1136/jitc-2020-001712
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
next ›
last »
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(560)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(983)
Commentary/Editorials
(153)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(242)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(437)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5026)
Press releases
(2)
